Exenatide’s Impact on Cardiac Surgery Outcomes: AHA 2024 Findings
Intravenous exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, did not significantly lower death, stroke, or organ failure risks during cardiopulmonary bypass-assisted cardiac surgery. This finding comes from the GLORIOUS trial, presented at the American Heart Association (AHA) Scientific Sessions 2024.
The study evaluated whether a 17.4μg intravenous infusion of exenatide could reduce complications during and after cardiac surgery compared to a placebo infusion. Dr. Sebastian Wiberg, an anesthesiologist from The Heart Centre, Copenhagen University Hospital Rigshospitalet, emphasized the lack of research in this area.
Exenatide, first approved in April 2005 by the FDA for type 2 diabetes management, was tested in a randomized, double-blind, placebo-controlled trial. Around 1,400 adults scheduled for elective or subacute cardiac surgery were enrolled from February 2016 to December 2021.
Key findings from the trial include the following:
– 5.8% of the exenatide group had a stroke, compared to 4.8% in the placebo group.
How do the findings of the GLORIOUS trial impact future research on cardiac surgery outcomes?
Interview with Dr. Sebastian Wiberg on the GLORIOUS Trial Findings
News Directory 3 (ND3): Thank you, Dr. Wiberg, for joining us today. The recent findings from the GLORIOUS trial raised several eyebrows in the medical community. Could you begin by summarizing the objectives of this study?
Dr. Sebastian Wiberg: Certainly. The GLORIOUS trial aimed to evaluate whether intravenous exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist originally approved for type 2 diabetes, could reduce complications such as death, stroke, or organ failure during and after cardiopulmonary bypass-assisted cardiac surgery. We compared a 17.4μg infusion of exenatide against a placebo infusion in around 1,400 adults undergoing elective or subacute cardiac surgery.
ND3: The results indicated that exenatide did not significantly lower risks of major complications. What were some key findings?
Dr. Wiberg: Yes, exactly. Firstly, we noted that 5.8% of patients in the exenatide group had a stroke compared to 4.8% in the placebo group, which suggests no substantial difference. Followingly, 9.8% of those treated with exenatide experienced worsening heart failure post-surgery, versus 10% in the placebo cohort. There was also a marginal difference in acute kidney injury rates — 4.8% for exenatide versus 5.3% for placebo. These numbers highlight the lack of a protective effect from exenatide in this surgical context.
ND3: Given that the study wasn’t able to show significant benefits, what are your thoughts on the implications of these findings?
Dr. Wiberg: It’s certainly disappointing, especially because we had hoped that exenatide would improve outcomes for patients undergoing cardiac surgery. However, these findings underscore a critical gap in our understanding and the need for further research. While exenatide has shown promise in other settings, its efficacy in this specific context appears limited. We must remain cautious about generalizing these results to other medications or patient types.
ND3: What do you believe should be the next steps following this trial?
Dr. Wiberg: I believe that we need additional trials to explore alternative strategies and treatments for improving outcomes in cardiac surgery. Specifically, we should focus on innovative therapeutic approaches, potential combinations of drugs, or even patient-centered interventions that can help mitigate risks during surgery. Collaboration among researchers, clinicians, and the industry will be instrumental in advancing this important area of investigation.
ND3: Thank you for your insights, Dr. Wiberg. Your contributions are essential in informing future research and improving patient care in cardiac surgery.
Dr. Wiberg: Thank you for having me. It’s crucial to continue these conversations as we work towards better outcomes for our patients.
– 9.8% of exenatide patients experienced worsening heart failure post-surgery, versus 10% in the placebo cohort.
– Acute kidney injury occurred in 4.8% of the exenatide group compared to 5.3% in the placebo group.
Dr. Wiberg noted these results might not apply to other medications or patient groups. He highlighted a need for additional trials to improve outcomes for patients undergoing cardiac surgery. He expressed disappointment that exenatide did not protect against heart failure or other complications.
These findings enhance understanding of cardiac surgery complications and inform future treatment strategies.